Multi-organ system and quality-of-life benefits sustained through three and a half years  86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year trialCOPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium,...

Media Release COPENHAGEN, Denmark; June 13, 2026Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) ineligible for anthracycline-based chemotherapy Results from the Phase 1b/2 EPCORE® NHL-2 trial show fixed-duration epcoritamab plus standard of care R-mini-CHOP demonstrated sustained minimal residual disease (MRD) negativity and durable remissions in elderly patients with newly diagnosed DLBCL ineligible for full dose R-CHOP Data were presented at the 2026 European Hematology Association (EHA) CongressGenmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients...

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects New analyses showed patients in mitapivat arm had clinically meaningful reduction in transfusion burden compared with placebo Patients in mitapivat arm who achieved hemoglobin response had clinically meaningful benefits across measures of sickle cell pain crises, fatigue, and other patient-reported outcomes Mitapivat was well-tolerated, with a safety profile consistent with previous trials of mitapivat in sickle cell disease Company to host investor conference call and webcast today at 9:00 a.m. ET (3:00 p.m. CEST)CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative...

 — Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures —    — Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS — — Company to hold conference call on Saturday, June 13, at 8 a.m. CT, 9 a.m. ET — BOSTON, June 13, 2026 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced preliminary data from a Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS) delivered during the Endocrine Society’s Annual...

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published in the New England Journal of MedicineCAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul, Türkiye. Results from the trial were simultaneously published in the...

WUHU, China, June 13, 2026 (GLOBE NEWSWIRE) — In a significant milestone for the global premium new energy vehicle industry, FREELANDER 8 made its first public appearance at the Abu Dhabi Investment Forum held at The Peninsula Shanghai on June 11, 2026. The showcase comes as FREELANDER prepares for its Middle East brand launch in Abu Dhabi. As one of the first international high-end investment forum to showcase the vehicle, the forum marks another significant step of FREELANDER’s global journey, with the Middle East identified as its first strategic launch market. Lucia Mao, CEO of FREELANDER International, delivered a keynote address to senior officials in a closed session, highlighting FREELANDER’s unique positioning as a British Premium Intelligent All-Terrain brand co-created by Jaguar Land Rover and Chery, building...

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) — Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The Series A-1 preferred investment...

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease. The rolling NDA was initiated in April...

New vertical extends ROMA’s sustainable-finance mandate into energy-efficient, behind-the-meter-powered digital infrastructure; Company is evaluating a pipeline of distributed, sub-50 MW AI/HPC investment opportunities, subject to diligence, definitive documentation, and board approval. ROMA, HONG KONG, June 12, 2026 (GLOBE NEWSWIRE) — ROMA Green Finance Limited (Nasdaq: ROMA) (“ROMA” or the “Company”) today announced the establishment of a dedicated investment vertical focused on Artificial Intelligence and High-Performance Computing (AI/HPC) infrastructure. The vertical extends the Company’s sustainable-finance and ESG advisory mandate into low-carbon, energy-efficient digital infrastructure. The vertical targets distributed, sub-50 MW compute assets paired with on-site behind-the-meter (BTM) power generation in low-cost energy...

MONTREAL, June 12, 2026 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is proceeding with a non-brokered private placement offering of units of the Company (the “Units”) to raise minimum gross proceeds of $1,200,000 and maximum gross proceeds of $2,200,000 (the “Unit Offering”). Each Unit will be offered at a price of $10,000 per Unit and is comprised of 200,000 common shares in the capital of the Company (the “Common Shares”) and 200,000 transferable share purchase warrants (the “Warrants”), resulting in the aggregate issuance of a minimum of 24,000,000 Common Shares and of a maximum of 44,000,000 Common Shares issued at a deemed price per share of $0.05 and a minimum of 24,000,000 Warrants and a maximum of 44,000,000 Warrants. Each Warrant entitles the holder to purchase a...